STRATA Skin Sciences Files 8-K
Ticker: SSKN · Form: 8-K · Filed: Apr 26, 2024 · CIK: 1051514
| Field | Detail |
|---|---|
| Company | Strata Skin Sciences, Inc. (SSKN) |
| Form Type | 8-K |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
STRATA Skin Sciences filed an 8-K, standard disclosure, check exhibits for details.
AI Summary
STRATA Skin Sciences, Inc. filed an 8-K on April 26, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates STRATA Skin Sciences is providing standard disclosures and financial information to the SEC. Investors should review the exhibits for any specific updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material adverse events.
Key Numbers
- 000-51481 — SEC File Number (Identifies the company's filing history with the SEC.)
- 13-3986004 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- STRATA Skin Sciences, Inc. (company) — Registrant
- MELA SCIENCES, INC. (company) — Former Company Name
- ELECTRO OPTICAL SCIENCES INC (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Horsham, Pennsylvania (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the company filing this report is STRATA Skin Sciences, Inc.
On what date was this report filed?
This report was filed on April 26, 2024.
What are the principal executive offices of STRATA Skin Sciences, Inc.?
The principal executive offices of STRATA Skin Sciences, Inc. are located at 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044.
Has the company undergone any previous name changes?
Yes, the company was formerly known as MELA SCIENCES, INC. and prior to that, ELECTRO OPTICAL SCIENCES INC.
Filing Stats: 702 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-04-26 17:20:55
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ
- $1.00 — 4 for the stock to trade above Nasdaq's $1.00 per share minimum bid price rule before
Filing Documents
- ef20027726_8k.htm (8-K) — 30KB
- ef20027726_ex99-1.htm (EX-99.1) — 11KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-022571.txt ( ) — 187KB
- sskn-20240426.xsd (EX-101.SCH) — 4KB
- sskn-20240426_lab.xml (EX-101.LAB) — 21KB
- sskn-20240426_pre.xml (EX-101.PRE) — 16KB
- ef20027726_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure On April 26, 2024, Strata Skin Sciences (the "Company") announced that that the Company will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 that will become effective at 11:59 p.m. Eastern Time on June 6, 2024. The Company's common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on June 7, 2024 under the existing symbol, SSKN, and under a new CUSIP number, 86272A 305. This reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's minimum bid price requirement for continued listing. Dr. Dolev Rafaeli, the Company's Vice-Chairman and CEO stated that "On October 26, 2023, shareholders approved a proposal for a reverse split between a ratio of 1-for-5 and 1-for-25. We have until June 6, 2024 for the stock to trade above Nasdaq's $1.00 per share minimum bid price rule before we would feel compelled to move forward with the reverse split. Today's announcement of the exact reverse split ratio simply satisfies the requirement from that shareholder approval that we announce the proposed reverse split ratio by April 26, 2024." The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 99.1 Strata Skin Sciences Press Release dated April 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: April 26, 2024 By: /s/ Christopher Lesovitz Christopher Lesovitz Chief Financial Officer